These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 33813386)

  • 1. Development of Antigen-specific Chimeric Antigen Receptor KHYG-1 Cells for Glioblastoma.
    Kang CH; Kim Y; Lee SM; Choi SU; Park CH
    Anticancer Res; 2021 Apr; 41(4):1811-1819. PubMed ID: 33813386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel AXL chimeric antigen receptor endows T cells with anti-tumor effects against triple negative breast cancers.
    Wei J; Sun H; Zhang A; Wu X; Li Y; Liu J; Duan Y; Xiao F; Wang H; Lv M; Wang L; Wu C
    Cell Immunol; 2018 Sep; 331():49-58. PubMed ID: 29935762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folate receptor 1 (FOLR1) targeted chimeric antigen receptor (CAR) T cells for the treatment of gastric cancer.
    Kim M; Pyo S; Kang CH; Lee CO; Lee HK; Choi SU; Park CH
    PLoS One; 2018; 13(6):e0198347. PubMed ID: 29874279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KHYG-1 Cells With EGFRvIII-specific CAR Induced a Pseudoprogression-like Feature in Subcutaneous Tumours Derived from Glioblastoma-like Cells.
    Nakazawa T; Murakami T; Natsume A; Nishimura F; Morimoto T; Matsuda R; Nakamura M; Yamada S; Nakagawa I; Park YS; Motoyama Y; Tsujimura T; Wakabayashi T; Nakase H
    Anticancer Res; 2020 Jun; 40(6):3231-3237. PubMed ID: 32487617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Human NK Cell Line Carrying CAR Targeting EGFRvIII Induces Antitumor Effects in Glioblastoma Cells.
    Murakami T; Nakazawa T; Natsume A; Nishimura F; Nakamura M; Matsuda R; Omoto K; Tanaka Y; Shida Y; Park YS; Motoyama Y; Nakagawa I; Yamada S; Tamura K; Takeshima Y; Takamura Y; Wakabayashi T; Nakase H
    Anticancer Res; 2018 Sep; 38(9):5049-5056. PubMed ID: 30194149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineering Axl specific CAR and SynNotch receptor for cancer therapy.
    Cho JH; Okuma A; Al-Rubaye D; Intisar E; Junghans RP; Wong WW
    Sci Rep; 2018 Mar; 8(1):3846. PubMed ID: 29497107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma.
    Brown CE; Aguilar B; Starr R; Yang X; Chang WC; Weng L; Chang B; Sarkissian A; Brito A; Sanchez JF; Ostberg JR; D'Apuzzo M; Badie B; Barish ME; Forman SJ
    Mol Ther; 2018 Jan; 26(1):31-44. PubMed ID: 29103912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracranial CAR-T cell delivery in glioblastoma patients.
    Vaughn-Beaucaire P; Choi MJ; Liang O; Lawler SE
    Trends Cancer; 2024 Jun; 10(6):478-480. PubMed ID: 38777680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD19 CAR-expressing iPSC-derived NK cells effectively enhance migration and cytotoxicity into glioblastoma by targeting to the pericytes in tumor microenvironment.
    Kong D; Kwon D; Moon B; Kim DH; Kim MJ; Choi J; Kang KS
    Biomed Pharmacother; 2024 May; 174():116436. PubMed ID: 38508081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RevCAR-expressing immune effector cells for targeting of Fn14-positive glioblastoma.
    Saleh HA; Mitwasi N; R Loureiro L; Kegler A; Soto KEG; Hoffmann L; Crespo E; Arndt C; Bergmann R; Bachmann M; Feldmann A
    Cancer Gene Ther; 2024 Sep; 31(9):1323-1334. PubMed ID: 38582787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres.
    Nehama D; Di Ianni N; Musio S; Du H; Patané M; Pollo B; Finocchiaro G; Park JJH; Dunn DE; Edwards DS; Damrauer JS; Hudson H; Floyd SR; Ferrone S; Savoldo B; Pellegatta S; Dotti G
    EBioMedicine; 2019 Sep; 47():33-43. PubMed ID: 31466914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric Antigen Receptor T Cells With Modified Interleukin-13 Preferentially Recognize IL13Rα2 and Suppress Malignant Glioma: A Preclinical Study.
    Kim K; Gwak HS; Han N; Hong EK; Choi BK; Lee S; Choi S; Park JH; Seok JH; Jeon Y; Cho H; Lee SJ; Lee Y; Nam KT; Song SW
    Front Immunol; 2021; 12():715000. PubMed ID: 34819930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges.
    Bagley SJ; Desai AS; Linette GP; June CH; O'Rourke DM
    Neuro Oncol; 2018 Oct; 20(11):1429-1438. PubMed ID: 29509936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic Efficacy of IL7/CCL19-Expressing CAR-T Cells in Intractable Solid Tumor Models of Glioblastoma and Pancreatic Cancer.
    Ohta K; Sakoda Y; Adachi K; Shinozaki T; Nakajima M; Yasuda H; Nagano H; Tamada K
    Cancer Res Commun; 2024 Sep; 4(9):2514-2524. PubMed ID: 39240078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape.
    Caforio M; Sorino C; Caruana I; Weber G; Camera A; Cifaldi L; De Angelis B; Del Bufalo F; Vitale A; Goffredo BM; De Vito R; Fruci D; Quintarelli C; Fanciulli M; Locatelli F; Folgiero V
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy for Glioblastoma: Adoptive T-cell Strategies.
    Choi BD; Maus MV; June CH; Sampson JH
    Clin Cancer Res; 2019 Apr; 25(7):2042-2048. PubMed ID: 30446589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2-targeting CAR-T cells show highly efficient anti-tumor activity against glioblastoma both in vitro and in vivo.
    Li X; Zhao L; Li W; Gao P; Zhang N
    Genes Immun; 2024 Jun; 25(3):201-208. PubMed ID: 38702509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CAR-T Cells Therapy in Glioblastoma: A Systematic Review on Molecular Targets and Treatment Strategies.
    Agosti E; Garaba A; Antonietti S; Ius T; Fontanella MM; Zeppieri M; Panciani PP
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma.
    Pituch KC; Miska J; Krenciute G; Panek WK; Li G; Rodriguez-Cruz T; Wu M; Han Y; Lesniak MS; Gottschalk S; Balyasnikova IV
    Mol Ther; 2018 Apr; 26(4):986-995. PubMed ID: 29503195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor effects of intracranial injection of B7-H3-targeted Car-T and Car-Nk cells in a patient-derived glioblastoma xenograft model.
    Tachi T; Kijima N; Kuroda H; Ikeda S; Murakami K; Nakagawa T; Yaga M; Nakagawa K; Utsugi R; Hirayama R; Okita Y; Kagawa N; Kishima H; Imai C; Hosen N
    Cancer Immunol Immunother; 2024 Oct; 73(12):256. PubMed ID: 39367952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.